Novartis adjusts industry unit names in preparation for Sandoz generics and biosimilars derivative – Endpoints Information

No­var­tis is mod­i­fy­ing its busi­ness gadgets’ names to re­flect its complete fo­cus on in­no­v­a­tive med­i­cines when San­doz spins off with gener­ics and biosim­i­lars lat­er this 12 months.

Two di­vi­sions will drop the phrases “in­no­v­a­tive med­i­cines” from their names — pass­ing from In­no­v­a­tive Med­i­cines In­ter­na­tion­al to In­ter­na­tion­al and from In­no­v­a­tive Med­i­cines US to sim­ply US. Re­seek & ear­ly de­vel­op­ment will now be known as Bio­med­ical Re­seek, drop­ping one phrase from its cur­hire In­sti­tutes for Bio­Med­ical Re­seek.